ES2513716T3 - Enzimas lecitina-colesteros acitransferasa modificadas - Google Patents

Enzimas lecitina-colesteros acitransferasa modificadas Download PDF

Info

Publication number
ES2513716T3
ES2513716T3 ES12003811.2T ES12003811T ES2513716T3 ES 2513716 T3 ES2513716 T3 ES 2513716T3 ES 12003811 T ES12003811 T ES 12003811T ES 2513716 T3 ES2513716 T3 ES 2513716T3
Authority
ES
Spain
Prior art keywords
cholesteros
acitransferase
enzymes
modified lecithin
lcat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12003811.2T
Other languages
English (en)
Inventor
Mingyue Zhou
Thomas Charles Boone
David Park Meininger
Margit Schwarz
Bei Shan
Wenyan Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2513716T3 publication Critical patent/ES2513716T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)

Abstract

Polinucleotido que codifica una proteina lecitina-colesterol aciltransferasa (LCAT) modificada, en el que la proteina LCAT modificada comprende una modificacion en la secuencia de aminoacidos de LCAT madura expuesta en SEQ ID NO: 1 o SEQ ID NO: 2 tal como se expone en la figura 2, y la modificación consiste en una sustitucion en el residuo de aminoacido 031 seleccionada del grupo que consiste en C31I, C31M, 031F, 031V, C31W, C31Y, 031R y 031H.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34

Claims (1)

  1. imagen1
ES12003811.2T 2007-07-26 2008-07-25 Enzimas lecitina-colesteros acitransferasa modificadas Active ES2513716T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95200707P 2007-07-26 2007-07-26
US952007P 2007-07-26

Publications (1)

Publication Number Publication Date
ES2513716T3 true ES2513716T3 (es) 2014-10-27

Family

ID=39864722

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08796592T Active ES2449483T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas
ES12003810.4T Active ES2559353T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas
ES12003811.2T Active ES2513716T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesteros acitransferasa modificadas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES08796592T Active ES2449483T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas
ES12003810.4T Active ES2559353T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas

Country Status (25)

Country Link
US (3) US8168416B2 (es)
EP (4) EP2489731B1 (es)
JP (5) JP5643643B2 (es)
KR (1) KR20100040937A (es)
CN (1) CN101855344B (es)
AU (1) AU2008279065B2 (es)
BR (1) BRPI0814310A2 (es)
CA (1) CA2694590A1 (es)
CR (1) CR11272A (es)
CY (2) CY1114857T1 (es)
DK (2) DK2489731T3 (es)
EA (1) EA201070187A1 (es)
ES (3) ES2449483T3 (es)
HR (1) HRP20140315T1 (es)
IL (1) IL203399A0 (es)
MX (1) MX348799B (es)
MY (1) MY159075A (es)
NZ (2) NZ582794A (es)
PL (2) PL2181190T3 (es)
PT (2) PT2181190E (es)
RS (1) RS53237B (es)
SG (1) SG186016A1 (es)
SI (2) SI2181190T1 (es)
UA (1) UA103304C2 (es)
WO (1) WO2009015314A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582794A (en) * 2007-07-26 2012-09-28 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
MX2011013065A (es) * 2009-06-12 2012-01-20 Alphacore Pharma Llc Uso de enzima lecitina-colesterol aciltransferasa (lcat) para tratar anemia y difucion de globulos rojos.
DK2566505T3 (da) 2010-05-06 2020-01-20 Alphacore Pharma Llc Fremføring af kolesterylester til steroidogene væv
WO2012114131A1 (en) * 2011-02-25 2012-08-30 University Of Patras Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld)
AU2012250614B2 (en) * 2011-05-05 2016-02-11 Pharma Cinq, Llc Complement factor B analogs and their uses
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
US10583104B2 (en) * 2014-08-06 2020-03-10 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
US20180265885A1 (en) * 2015-01-29 2018-09-20 Plantvax, Inc. Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
WO2019092584A1 (en) * 2017-11-07 2019-05-16 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
JP7460540B2 (ja) * 2018-05-22 2024-04-02 ディーエスエム アイピー アセッツ ビー．ブイ． 修飾ステロールアシルトランスフェラーゼ
US11612619B2 (en) 2018-11-01 2023-03-28 National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Compostions and methods for enabling cholesterol catabolism in human cells
JP2023515302A (ja) 2020-02-28 2023-04-13 リペア・バイオテクノロジーズ・インコーポレイテッド 微生物コレステロール異化遺伝子の標的化発現による過剰脂質の低下

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS63167409A (ja) 1986-12-27 1988-07-11 Yamaha Corp 磁気記録体
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
JP3254219B2 (ja) 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR100431038B1 (ko) 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
DE69636907T2 (de) * 1995-11-09 2007-11-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
EP0973914B1 (en) * 1997-04-11 2006-12-13 Takeda Pharmaceutical Company Limited Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
DK0974356T3 (da) 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001005943A2 (en) 1999-07-14 2001-01-25 Betagene, Inc. Lcat recombinant cell line compositions and methods
ATE540681T1 (de) * 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
NZ582794A (en) * 2007-07-26 2012-09-28 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes

Also Published As

Publication number Publication date
CR11272A (es) 2010-05-26
ES2559353T3 (es) 2016-02-11
EP2181190B1 (en) 2014-01-08
DK2489731T3 (en) 2014-11-17
PL2181190T3 (pl) 2014-06-30
JP2010534479A (ja) 2010-11-11
ES2449483T3 (es) 2014-03-19
EP2522721A3 (en) 2013-01-23
RS53237B (sr) 2014-08-29
EP2489731B1 (en) 2014-08-27
CA2694590A1 (en) 2009-01-29
JP2020058366A (ja) 2020-04-16
JP2018161134A (ja) 2018-10-18
SI2181190T1 (sl) 2014-04-30
UA103304C2 (ru) 2013-10-10
JP6033258B2 (ja) 2016-11-30
EP2181190A2 (en) 2010-05-05
NZ582794A (en) 2012-09-28
CN101855344B (zh) 2015-12-09
US20140287479A1 (en) 2014-09-25
EP2489730B1 (en) 2015-12-30
WO2009015314A2 (en) 2009-01-29
PL2489731T3 (pl) 2015-01-30
EP2489731A1 (en) 2012-08-22
DK2181190T3 (da) 2014-03-31
MY159075A (en) 2016-12-15
HRP20140315T1 (hr) 2014-05-09
PT2181190E (pt) 2014-02-24
BRPI0814310A2 (pt) 2015-01-06
US8703926B1 (en) 2014-04-22
KR20100040937A (ko) 2010-04-21
NZ597885A (en) 2013-08-30
EP2522721A2 (en) 2012-11-14
CN101855344A (zh) 2010-10-06
EP2489730A1 (en) 2012-08-22
EP2522721B1 (en) 2016-05-04
WO2009015314A3 (en) 2009-03-12
AU2008279065B2 (en) 2013-12-12
CY1115573T1 (el) 2017-01-04
MX348799B (es) 2017-06-29
US8168416B2 (en) 2012-05-01
US20090081182A1 (en) 2009-03-26
SG186016A1 (en) 2012-12-28
JP5643643B2 (ja) 2014-12-17
EA201070187A1 (ru) 2010-08-30
JP2016182136A (ja) 2016-10-20
CY1114857T1 (el) 2016-12-14
JP2014198047A (ja) 2014-10-23
US9006408B2 (en) 2015-04-14
IL203399A0 (en) 2011-07-31
SI2489731T1 (sl) 2014-12-31
PT2489731E (pt) 2014-09-15
HK1138039A1 (en) 2010-08-13
AU2008279065A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2572955T3 (es) Composiciones y usos para el tratamiento de la proteinosis alveolar pulmonar
ES2568803T3 (es) Reducción del contenido de ácidos grasos saturados en semillas de plantas
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
ES2687294T3 (es) Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
CO6210757A2 (es) Proeina de fusion que comprende prame o un fragmento inmunogenico del mismo
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
AR074311A1 (es) Variantes de subtilisina aislada de bacillus, con actividad proteolitica
EA201000327A1 (ru) Белок
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
MX2017016610A (es) Metodos de reduccion de olor.
PY18107826A (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
ECSP077246A (es) Formulaciones Estabilizadoras
AR072495A1 (es) Secuencia reguladora de las plantas proveniente de un gen de maiz
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
MX2022003472A (es) Mananasa para formulaciones que tienen ph 5-12.
ES2609586T3 (es) Secuencias de nucleótidos y aminoácidos que codifican una proteína exportada 1 derivada de Plasmodium vivax y usos de las mismas
AR087719A2 (es) Celula de planta transformada, cultivo de tejidos y planta transgenica
WO2016036635A8 (en) Chromobacterium subtsugae genes